Statute Details
- Title: Medicines (Non-Medicinal Products) Order 2023
- Act Code: MA1975-S805-2023
- Legislation Type: Subsidiary Legislation (SL)
- Authorising Act: Medicines Act 1975
- Enacting Authority: Minister for Health (exercising powers under section 3(4)(c) of the Medicines Act 1975)
- Commencement: 18 December 2023
- Key Provisions (from extract): Sections 1–3
- Status: Current version as at 27 March 2026 (per the legislation portal)
- Related Legislation: Health Products Act 2007; Medicines Act 1975; Medicines (Non-Medicinal Products) (Consolidation) Order (O 3) (revoked)
What Is This Legislation About?
The Medicines (Non-Medicinal Products) Order 2023 is a Singapore subsidiary legislation made under the Medicines Act 1975. Its practical purpose is to clarify the boundary between what counts as a “medicinal product” under the Medicines Act and what does not. In other words, it helps determine when a substance or compound is regulated as a medicine (with the attendant regulatory requirements) versus when it falls outside that definition because it is usable in the manufacture of a “health product” under the Health Products Act 2007.
At its core, the Order addresses a definitional issue: certain substances may be used in manufacturing health products, and the Order ensures that such substances are not treated as “medicinal products” for the purposes of the Medicines Act. This is important for manufacturers, importers, and distributors who need to understand which regulatory regime applies to their ingredients and products.
Although the Order is short, it has significant compliance implications. A misclassification can trigger licensing, product registration, quality control, labelling, and enforcement consequences under the Medicines Act. Conversely, correct classification can reduce unnecessary regulatory burdens and align compliance with the appropriate statutory framework.
What Are the Key Provisions?
Section 1: Citation and commencement provides the formal identification and effective date of the Order. The Order is cited as the “Medicines (Non‑Medicinal Products) Order 2023” and comes into operation on 18 December 2023. For practitioners, the commencement date matters when assessing transitional arrangements, regulatory audits, and whether conduct occurred before or after the definitional clarification took effect.
Section 2: Substances and articles that are not medicinal products for purposes of Act is the substantive provision. It states that, for the purposes of the Medicines Act, a “medicinal product” does not include any substance or compound that is usable in the manufacture of a health product within the meaning of section 2(1) of the Health Products Act 2007 as a pharmacologically active constituent.
This wording is legally precise and should be read carefully. The exemption is not framed around the substance’s name or general category; it is framed around its use and its function in the manufacture of a health product. Three elements are embedded in the definition:
- Usable in the manufacture of a health product: the substance must be capable of being used as an input to manufacture a health product as defined under the Health Products Act.
- Pharmacologically active constituent: the substance must serve as a pharmacologically active constituent in that health product manufacturing context.
- For purposes of the Medicines Act: the effect is definitional—such a substance is excluded from the Medicines Act’s “medicinal product” concept.
In plain language, Section 2 recognises that some ingredients may have pharmacological activity, yet still be regulated as part of the health product framework rather than as medicines—provided they are used as pharmacologically active constituents in manufacturing health products. This is a classic regulatory boundary-setting mechanism: it prevents the Medicines Act from automatically capturing ingredients merely because they are pharmacologically active, so long as they are used in the health product manufacturing pathway.
Section 3: Revocation revokes the prior “Medicines (Non‑Medicinal Products) (Consolidation) Order (O 3).” This indicates that the 2023 Order supersedes the earlier consolidated instrument. For legal compliance, revocation means that references to the revoked Order should be updated, and any internal compliance documentation should be revised to reflect the current definitional position.
How Is This Legislation Structured?
The Order is structured as a short, three-section instrument:
- Section 1 sets out the citation and commencement date.
- Section 2 provides the definitional rule that excludes certain substances and compounds from the Medicines Act’s “medicinal product” concept, specifically where they are usable in manufacturing health products as pharmacologically active constituents.
- Section 3 revokes the earlier consolidation Order.
There are no schedules or detailed procedural provisions in the extract provided. The Order’s legal work is therefore done through its definitional clarification rather than through administrative processes.
Who Does This Legislation Apply To?
Although the Order is directed at the interpretation of the Medicines Act, it affects a wide range of stakeholders in the health and life sciences supply chain. In practice, it is relevant to:
- Manufacturers of health products who use pharmacologically active constituents in their formulations;
- Suppliers and distributors of substances or compounds that are intended for use in manufacturing health products;
- Importers and wholesalers who handle ingredients that may otherwise be argued to fall within “medicinal products”;
- Regulatory compliance teams and legal counsel advising on classification, licensing, and product regulatory pathways.
The Order applies “for the purposes of the Act,” meaning its effect is interpretive: it guides how the Medicines Act’s definitions are applied to substances and compounds. It does not, by itself, create licensing obligations; rather, it determines whether the Medicines Act’s medicinal product framework is engaged.
Because Section 2 depends on whether the substance is usable in the manufacture of a “health product” and is a “pharmacologically active constituent,” the applicability will turn on factual and regulatory characterisation. Parties should be prepared to evidence the intended use in health product manufacturing and the constituent role within that manufacturing context.
Why Is This Legislation Important?
This Order is important because it resolves a boundary problem that frequently arises in regulatory practice: the same ingredient may be capable of being used in different product categories, and pharmacological activity can blur the line between medicines and health products. By carving out substances usable as pharmacologically active constituents in health product manufacturing, the Order provides legal certainty and reduces the risk of over-regulation under the Medicines Act.
For practitioners, the key significance lies in how it can affect compliance strategy and risk assessment. If a substance is excluded from “medicinal product” status under the Medicines Act, the regulatory pathway may shift toward the Health Products Act 2007 framework. That can influence which approvals are required, what labelling and claims rules apply, and which enforcement regime is relevant.
Conversely, the definitional exclusion is not automatic for all pharmacologically active substances. The exclusion is conditional on the substance being usable in manufacturing a health product (as defined in the Health Products Act) and being used as a pharmacologically active constituent. Therefore, the Order is best understood as a targeted clarification that requires careful documentation and classification analysis.
Finally, the revocation of the earlier consolidation Order means that compliance teams should ensure they are relying on the current legal text. In audits, enforcement responses, or due diligence, outdated references can undermine the credibility of a compliance position. The commencement date (18 December 2023) also matters for assessing whether classification decisions were made under the prior regime or the current one.
Related Legislation
- Health Products Act 2007
- Medicines Act 1975
- Medicines (Non-Medicinal Products) (Consolidation) Order (O 3) (revoked by Section 3)
Source Documents
This article provides an overview of the Medicines (Non-Medicinal Products) Order 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.